Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea
Journal of Diabetes Investigation · 2026-08 · 17 (8) · 1367-1378
DOI: 10.1111/jdi.70341 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 20.05.2026. Verfasst von Yun Young Choi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Thiazolidinediones, Cardiovascular Diseases, Hypoglycemic Agents. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT), Chong Kun Dang Pharmaceutical Corp, Ministry of Science and ICT, South Korea.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Thiazolidinediones (TZDs) are antidiabetic agents recognized for their effectiveness in secondary cardiovascular prevention; however, their role in primary prevention remains uncertain. This study evaluated the primary cardiovascular preventive effect of TZDs in patients with type 2 diabetes mellitus (T2DM).
Methods
Using the nationwide health claims database, we conducted a cohort study including 1,958,643 adults with T2DM and no prior history of cardiovascular disease. TZD users were compared with dipeptidyl peptidase‐4 inhibitor (DPP‐4i) users as active comparators. After 1:1 propensity score matching (PSM), major cardiovascular events—composite of myocardial infarction (MI), stroke, hospitalization for heart failure (HF), and all‐cause mortality—were compared using Cox proportional hazards models.
Results
In the PSM cohort consisting of 47,536 TZD users and 47,536 DPP‐4i users, TZD users were associated with a lower risk of major cardiovascular events (HR 0.85, 95% CI 0.82–0.88). TZD users had lower risks of MI (HR 0.72, 95% CI 0.64–0.82), stroke (HR 0.84, 95% CI 0.78–0.90), and all‐cause mortality (HR 0.86, 95% CI 0.82–0.90), with no difference in HF hospitalizations.
Conclusions
TZD use was associated with a reduced risk of major cardiovascular events in T2DM patients, suggesting a potential role of TZDs in primary cardiovascular prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
- Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, South Korea.
- Yonsei Institute for Digital health, Yonsei University, Seoul, South Korea.
ORCID-Profile: Yun Young Choi, Minyoul Baik, Jinkwon Kim
Förderung
- National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT)
- Chong Kun Dang Pharmaceutical Corp
- Ministry of Science and ICT, South Korea
Zitieren
APA
Choi, Y. Y., Jeon, J., Baik, M., Yoo, J., & Kim, J. (2026). Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea. Journal of Diabetes Investigation, 17(8), 1367-1378. https://doi.org/10.1111/jdi.70341
Vancouver
Choi YY, Jeon J, Baik M, Yoo J, Kim J. Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea. Journal of Diabetes Investigation. 2026;17(8):1367-1378. doi:10.1111/jdi.70341
BibTeX
@article{Choi2026,
author = {Choi, Yun Young and Jeon, Jimin and Baik, Minyoul and Yoo, Joonsang and Kim, Jinkwon},
title = {Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea},
journal = {Journal of Diabetes Investigation},
year = {2026},
volume = {17},
number = {8},
pages = {1367--1378},
doi = {10.1111/jdi.70341}
}
EUVIMED